MedTrace Logo

Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study

NCT03903406 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-04-04

No results posted yet for this study

Summary

The purpose of this pilot study is to examine changes in patient-reported outcomes in patients with RRMM receiving triple therapy with ixazomib in combination with LenDex in a real world setting as well as to analyze clinical outcomes and safety of this treatment modality.

Conditions

  • Relapsed and/or Refractory Multiple Myeloma

Interventions

DRUG

ixazomib in combination with lenalidomide and dexamethasone

Patients with RRMM who have received at least one prior therapy will receive Ixazomib in combination with lenalidomide and dexamethasone within the routine clinical practice in accordance with prescription. Duration of therapy - until disease progression or unacceptable toxicity.

Sponsors & Collaborators

  • Multinational Center for Quality of Life Research, Russia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-31
Primary Completion
2021-11-30
Completion
2021-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03903406 on ClinicalTrials.gov